Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 25;40:163–175. doi: 10.1016/j.ebiom.2019.01.030

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Published by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 1 — The expression and prognostic significance of SLC2A4RG in glioma. (a) SLC2A4RG mRNA expression detected via RT-PCR in normal brains and human glioma specimens with different WHO grades. (b, d, and e) Total, cytoplasmic, and nuclear immunoreactivity scores of SLC2A4RG in the second independent cohort of normal brains, LGGs, and HGG. (c) Representative staining images of SLC2A4RG in normal brains and gliomas. (f and g) The percentages of cytoplasmic SLC2A4RG (f) and nuclear SLC2A4RG (g) in these specimens calculated based on b, d, e. (h) The protein level of nuclear SLC2A4RG analyzed in the third independent cohort containing normal brains, LGG and HGG specimens by western blot. (i) The fold change of SLC2A4RG protein is normalized to Histone 3A. (j) Kaplan-Meier curves were used to analyze the relationships between the total/cytoplasmic/nuclear SLC2A4RG immunoreactivity level and OS in glioma patients from the second cohort. Student's t-test, ns, no significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001.